IP Library › Granted Patent US 12,246,065
Granted Patent B2
US 12,246,065 · App. 18/418,078 · Granted Mar 11, 2025

Immunotherapy of cancer patients using CAR T or CAR NK cells combined with hematopoietic cells that have a modified or deleted target antigen

Inventors: Michael Lutteropp (Bergisch Gladbach, DE); Anne Richter (Bergisch Gladbach, DE); Andrew Kaiser (Bergisch Gladbach, DE); Mario Assenmacher (Bergisch Gladbach, DE); Stefan Miltenyi (Bergisch Gladbach, DE)
Assignee: Miltenyi Biotec B.V. & Co. Kg
A61K39/3955A61K35/12A61K38/1774A61K39/0005A61K39/4611A61K39/4631A61K39/464424A61K2035/124A61K2039/5156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,246,065
App. No.
18/418,078
Granted
Mar 11, 2025
Kind
B2
Abstract

The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.

Claims (43)

1. A method of treating a patient having a cancer characterized by malignant cells that express a target antigen,

wherein the target antigen is also expressed on some non-malignant cells in the patient, the method comprising:

(a) producing a first cell population by:

(i) obtaining immune effector cells; and

(ii) genetically modifying the immune effector cells to produce engineered effector cells that express a receptor that recognizes the target antigen;

(b) producing a second cell population by:

(i) obtaining non-malignant hematopoietic cells; and

(ii) genetically modifying the non-malignant hematopoietic cells to produce engineered hematopoietic cells that are resistant to recognition by the engineered effector cells; and

(c) administering the first and the second cell population to the patient.

2. The method of claim 1 , wherein the receptor is a T cell receptor (TCR) or a chimeric antigen receptor (CAR).

3. The method of claim 1 , wherein the immune effector cells are cells with cytotoxic effector function.

4. The method of claim 1 , wherein the target antigen is a protein expressed at or near the surface membrane of the malignant cells.

5. The method of claim 4 , wherein the target antigen is a membrane associated intracellular protein.

6. The method of claim 1 , wherein the engineered effector cells recognize the malignant cells in a non-HLA-restricted manner.

7. The method of claim 1 , wherein the receptor recognizes a complex of a peptide derived from the target antigen presented by a human leukocyte antigen (HLA) molecule, wherein the complex is not formed by the engineered hematopoietic cells.

8. The method of claim 7 , wherein the engineered effector cells do not express an HLA allotype recognized by the receptor.

9. The method of claim 1 , wherein the engineered hematopoietic cells do not express the target antigen.

10. The method of claim 1 , wherein the engineered hematopoietic cells express a truncated form of the target antigen that is not recognized by the receptor.

11. The method of claim 1 , wherein the target antigen is expressed on the engineered hematopoietic cells at a lower density than it is expressed on the malignant cells.

12. The method of claim 1 , wherein the engineered hematopoietic cells express an altered form of the target antigen that comprises one or a plurality of amino acid substitutions or deletions, whereby the receptor does not recognize the altered form of the target antigen.

13. The method of claim 12 , wherein the altered form of the target antigen expressed by the engineered hematopoietic cells is over 90% identical to the target antigen expressed on the malignant cells.

14. The method of claim 1 , wherein the receptor on the engineered effector cells has a binding affinity for the engineered hematopoietic cells that is one tenth or less of the binding affinity for the malignant cells.

15. The method of claim 1 , wherein the cancer is a hematopoietic cell cancer.

16. The method of claim 1 , wherein the immune effector cells and the non-malignant hematopoietic cells are both obtained from the patient.

17. The method of claim 1 , wherein the immune effector cells and the non-malignant hematopoietic cells are obtained from donor(s) who are allogeneic to the patient.

18. The method of claim 1 , wherein the immune effector cells and the hematopoietic cells are obtained from different donors.

19. The method of claim 1 , wherein the engineered hematopoietic cells are administered to the patient before the engineered effector cells.

20. The method of claim 1 , wherein the engineered hematopoietic cells are administered to the patient at the same time or after administration of the engineered effector cells.

21. A method of preparing two cell populations for treating a patient having a cancer characterized by malignant cells that express a target antigen

wherein the target antigen is also expressed on some non-malignant cells in the patient, the method comprising:

(a) producing a first cell population by:

(i) obtaining immune effector cells;

(ii) genetically modifying the immune effector cells to produce engineered effector cells that bear a receptor that recognizes the target antigen; and

(iii) formulating the engineered effector cells for administration to the patient; and

(b) producing a second cell population by:

(i) obtaining non-malignant hematopoietic cells from a second donor;

(ii) genetically modifying the non-malignant hematopoietic cells to produce engineered hematopoietic cells that are resistant to recognition by the engineered effector cells; and

(iii) formulating the engineered hematopoietic cells for administration to the patient.

22. The method of claim 21 , wherein the immune effector cells and the non-malignant hematopoietic cells are both obtained from the patient.

23. The method of claim 21 , wherein the immune effector cells and the non-malignant hematopoietic cells are obtained from donor(s) who are allogeneic to the patient.

24. The method of claim 21 , wherein the immune effector cells and the hematopoietic cells are obtained from different donors.

25. The method of claim 21 , wherein the target antigen is a cluster of differentiation (CD) antigen that is characteristic of myeloid leukemia cells.

26. The method of claim 21 , whereby the first cell population and the second cell population are combined into a single formulation.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2024
From: LUTTEROPP, MICHAEL; RICHTER, ANNE; KAISER, ANDREW; ASSENMACHER, MARIO; MILTENYI,, STEFAN
To: MILTENYI BIOTEC GMBH
Reel/Frame 067499/0027 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2024
From: MILTENYI BIOTEC GMBH
To: MILTENYI BIOTEC B.V. & CO. KG
Reel/Frame 067505/0638 →
Priority Claims (1)
DE 102014224071.9 · Nov 26, 2014 · national
Continuity (5)
Continuation 18186730 · Mar 20, 2023
Continuation 17318914 · May 12, 2021
Continuation 16005466 · Jun 11, 2018
Division 14952448 · Nov 25, 2015
Related Publication 20240269275A1 · Aug 15, 2024
References Cited (143)
US 10137155B2 · Mukherjee et al. · 2018 [cited by applicant]
US 10201606B2 · Lutteropp et al. · 2019 [cited by applicant]
US 10210606B2 · Pandev et al. · 2019 [cited by applicant]
US 10548922B2 · Gill et al. · 2020 [cited by applicant]
US 10912799B2 · Mukherjee et al. · 2021 [cited by applicant]
US 11033619B2 · Lutteropp et al. · 2021 [cited by applicant]
US 11419935B2 · Lutteropp et al. · 2022 [cited by applicant]
US 11883494B2 · Lutteropp et al. · 2024 [cited by applicant]
US 20120309091A1 · Ando et al. · 2012 [cited by applicant]
US 20140242701A1 · Shiku · 2014 [cited by examiner]
US 20160144026A1 · Lutteropp et al. · 2016 [cited by applicant]
EP 2711418 · 2014 [cited by applicant]
EP 3025719B1 · 2018 [cited by applicant]
EP 3105317B1 · 2018 [cited by applicant]
WO 2012012667 · 2012 [cited by applicant]
WO 2012082841A2 · 2012 [cited by applicant]
WO 2014059173 · 2014 [cited by applicant]
WO 2014191128A1 · 2014 [cited by applicant]
WO 2015121454A1 · 2015 [cited by applicant]
WO 2016011210A2 · 2016 [cited by applicant]
WO 2017066760 · 2017 [cited by applicant]
WO 2017079400A1 · 2017 [cited by applicant]
Autologous T-Cells Genetically Modified at the CCR5 Gene by Zink Finger Nucleases SB-728 for HIV, Clinical study listed on Clinicaltrials.gov website under Identifier NCT00842634, Accessed from Internet on Mar. 12, 2021… [cited by applicant]
CAR T-Cell Therapy: Engineering Patients' Immune Cells to Treat Their Cancers, National Cancer Institute, Available online at: http://www.cancer.gov/aDout-cancer/treatment/research/car-t-cens, May 18, 2015, 6 pages. [cited by applicant]
CD33 [Uniport ID: P20138], Available Online at: https://register.epo.org/application?number=EP15196309&Ing=en&tab=doclist, Accessed from Internet on Feb. 15, 2021, 45 pages. [cited by applicant]
Experimenter: Dr. Dominik Lock / Team Coordinator R&D Gene Immunotherapy, 4 pages. [cited by applicant]
Experimenter: Dr. Eleni Papanikolaott / Manager, Hemopoletic Stem Cell Gene Therapy, 8 pages. [cited by applicant]
Protein (Amino Acid) Sequence Data for CD33, CD34, CD45, CD123, CD133, and CD19, From Swiss-Prot database dated Sep. 5 and Oct. 3, 2012, 2012, 9 pages. [cited by applicant]
Raji (ATCC® CCL86™), Available online at: http://www.lgcstandards-atcc.org/Products/All/CCL-86.aspx?geo, Accessed from Internet on Nov. 11, 2019, 2 pages. [cited by applicant]
Sequences of Antigens, 16 pages. [cited by applicant]
Vor Biopharma, Available online at: http://www.vorbiopharma.com, Accessed from Internet on: Nov. 18, 2019, 3 pages. [cited by applicant]
U.S. Appl. No. 14/952,448, Final Office Action mailed on Jun. 21, 2018, 8 pages. [cited by applicant]
U.S. Appl. No. 14/952,448, First Action Interview Pilot Program Pre-Interview Communication, mailed on Jan. 23, 2018, 3 pages. [cited by applicant]
U.S. Appl. No. 14/952,448, Notice of Allowability mailed on Dec. 28, 2018, 2 pages. [cited by applicant]
U.S. Appl. No. 14/952,448, Notice of Allowance mailed on Nov. 30, 2018, 8 pages. [cited by applicant]
U.S. Appl. No. 14/952,448, Restriction Requirement mailed on Aug. 10, 2017, 8 pages. [cited by applicant]
U.S. Appl. No. 16/005,466, First Action Interview Pilot Program Pre-Interview Communication mailed on Nov. 30, 2020, 3 pages. [cited by applicant]
U.S. Appl. No. 16/005,466, Notice of Allowance mailed on Apr. 5, 2021, 9 pages. [cited by applicant]
U.S. Appl. No. 16/005,466, Supplemental Notice of Allowability mailed on May 13, 2021, 2 pages. [cited by applicant]
U.S. Appl. No. 17/318,914, Non-Final Office Action mailed on Feb. 13, 2023, 17 pages. [cited by applicant]
Anaya et al., Autoimmunity: From Bench to Bedside, El Rosario University Press, Jul. 18, 2013, 70 pages. [cited by applicant]
Anurathapan et al., Engineered T Cells for Cancer Treatment, Cytotherapy, vol. 16, No. 6, Jun. 2014, 35 pages. [cited by applicant]
Bailey et al., M.V. Gene Editing for Immune Cell Therapies, Nature Biotechnology, vol. 37, No. 12, Dec. 2019, pp. 1425-1434. [cited by applicant]
Belicha-Villanueva et al., What Is the Role of Alternate Splicing in Antigen Presentation by Major Histocompatibility Complex Class I Molecules, Immunologic Research, vol. 46, No. 1-3, Mar. 2010, pp. 1-14. [cited by applicant]
Bendall et al., Expression of CD44 Variant Exons in Acute Myeloid Leukemia is more Common and More Complex than that Observed in Normal Blood, Bone Marrow or CD34+ Cells, Leukemia, vol. 14, No. 7, Jul. 2000, pp. 1239-12… [cited by applicant]
Bergom et al., An Alternatively Spliced Isoform of Pecam-1 is Expressed at High Levels in Human and Murine Tissues, and Suggests a Novel Role for the C-Terminus of PECAM-1 in Cytoprotective Signalling, Journal of Cell S… [cited by applicant]
Borot et al., Gene-Edited Stem Cells Enable CC33-Directed Immune Therapy for Myeloid Malignancies, Proceedings of the National Academy of Sciences USA, vol. 116, No. 24, Jun. 11, 2019, pp. 11978-11987. [cited by applicant]
Brentjens et al., CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia, Science Translational Medicine, vol. 5, No. 177, Mar. 20, 2013, pp. 1-19. [cited by applicant]
Bubien et al., Transfection of the CD20 Cell Surface Molecule Into Ectopic Cell Types Generates a Ca2+ Conductance Found Constitutively in B Lymphocytes, Journal of Cell Biology, vol. 121, No. 5, Jun. 1993, pp. 1121-113… [cited by applicant]
Casucci et al., CD44v6-Targeted T Cells Mediate Potent Antitumor Effects Against Acute Myeloid Leukemia and Multiple Myeloma, Blood, vol. 122, No. 20, Nov. 14, 2013, pp. 3461-3472. [cited by applicant]
Chen et al., A New Isoform of Interleukin-3 Receptor a with Novel Differentiation Activity and High Affinity Binding Mode, The Journal of Biological Chemistry, vol. 284, No. 9, Feb. 27, 2009, pp. 5763-5773. [cited by applicant]
Cho et al., Targeted Genome Engineering in Human Cells with the Cas9 RNA-Guided Endonuclease, Nature Biotechnology, vol. 31, No. 3, Mar. 2013, pp. 230-232. [cited by applicant]
Cong et al., Multiplex Genome Engineering Using CRISPR/Cas Systems, Science, vol. 339, No. 6121, Feb. 15, 2013, pp. 819-823. [cited by applicant]
Cradick et al., CRISPR/Cas9 Systems Targeting-Globin and CCR5 Genes have Substantial off-target Activity, Nucleic Acids Research, vol. 41, No. 20, Aug. 11, 2013, pp. 9584-9592. [cited by applicant]
Davila et al., Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia, Science Translational Medicine, vol. 6, No. 224, Feb. 19, 2014, pp. 1-23. [cited by applicant]
De Oliveira et al., Modification of Hematopoietic Stem/progenitor Cells with CD19-Specific Chimeric Antigen Receptors as a Novel Approach for Cancer Immunotherapy, Human Gene Therapy, vol. 24, No. 10, Oct. 2013, pp. 824… [cited by applicant]
Ding et al., Single Nucleotide Polymorphisms of CD20 Gene and Their Relationship with Clinical Efficacy of R-CHOP in Patients with Diffuse Large B Cell Lymphoma, Cancer Cell International, vol. 13, No. 1, Jun. 2013, 8 p… [cited by applicant]
European Application No. EP1519609.7, Response to the Opposition mailed on Nov. 18, 2019, 39 pages. [cited by applicant]
European Application No. EP15196309, European Search Report mailed on Feb. 17, 2016, 2 pages. [cited by applicant]
European Application No. EP15196309.7, Amended Description with Annotations for New MR mailed on Sep. 10, 2021, 46 pages. [cited by applicant]
European Application No. EP15196309.7, Auxiliary Request (Marked-Up) mailed on Jan. 17, 2023, 13 pages. [cited by applicant]
European Application No. EP15196309.7, Auxiliary Request (Marked-up) mailed on Sep. 7, 2021, 21 pages. [cited by applicant]
European Application No. EP15196309.7, Brief Communication—Opposition Proceedings mailed on Mar. 23, 2021, 16 pages. [cited by applicant]
European Application No. EP15196309.7, Communication of the Board of Appeal pursuant to Article 15(1) of the Rules of Procedure of the Boards of Appeal mailed on Dec. 8, 2022, 14 pages. [cited by applicant]
European Application No. EP15196309.7, Decision Revoking the European Patent mailed on Apr. 28, 2021, 27 pages. [cited by applicant]
European Application No. EP15196309.7, Letter Accompanying Subsequently Filed Items mailed on Jan. 17, 2023, 13 pages. [cited by applicant]
European Application No. EP15196309.7, Main Request During Appeals Procedure mailed on Sep. 7, 2021, 2 pages. [cited by applicant]
European Application No. EP15196309.7, Notice of Appeal mailed on Apr. 28, 2021, 4 pages. [cited by applicant]
European Application No. EP15196309.7, Oppenent's Reply to the Board's Preliminary Opinion and the Patentee's (P's) Submission of Jan. 17, 2023 and Mar. 16, 2023, mailed on May 19, 2023, 18 pages. [cited by applicant]
European Application No. EP15196309.7, Opposition—Auxiliary Requests Accompanying Written Submission: Miltenyi mailed on Mar. 2, 2021, 31 pages. [cited by applicant]
European Application No. EP15196309.7, Opposition—Communication in Advance of Oral Proceedings: Opponent mailed on Mar. 5, 2021, 45 pages. [cited by applicant]
European Application No. EP15196309.7, Opposition—Consolidated List of Cited Documents mailed on Mar. 17, 2021, 4 pages. [cited by applicant]
European Application No. EP15196309.7, Opposition—Response to Opponent's Submission of Mar. 5, 2021: Miltenyi mailed on Mar. 12, 2021, 9 pages. [cited by applicant]
European Application No. EP15196309.7, Opposition—Response to Patentee's Submission of Jan. 19, 2021: Opponent mailed on Mar. 5, 2021, 16 pages. [cited by applicant]
European Application No. EP15196309.7, Opposition—Results of Oral Proceedings mailed on Mar. 19, 2021, 1 page. [cited by applicant]
European Application No. EP15196309.7, Opposition—Supplementary Response to the Objection Raised by the Opponent: Miltenyi mailed on Mar. 17, 2021, 14 pages. [cited by applicant]
European Application No. EP15196309.7, Opposition—Written Submission in Response to Communication from Opposition Division: Miltenyi mailed on Mar. 2, 2021, 13 pages. [cited by applicant]
European Application No. EP15196309.7, Oral Proceedings: Confirmation Interpreters mailed on Jul. 13, 2023, 2 pages. [cited by applicant]
European Application No. EP15196309.7, Reply to Appeal mailed on Jan. 21, 2022, 41 pages. [cited by applicant]
European Application No. EP15196309.7, Response to First Summons mailed on Aug. 19, 2020, 16 pages. [cited by applicant]
European Application No. EP15196309.7, Response to Opposition mailed on Aug. 21, 2020, 25 pages. [cited by applicant]
European Application No. EP15196309.7, Response to Second Summons mailed on Jan. 19, 2021, 25 pages. [cited by applicant]
European Application No. EP15196309.7, Response to the Communication pursuant to Article 15(1) of the Rules of Procedure of the Boards of Appeal mailed on Jan. 17, 2023, 13 pages. [cited by applicant]
European Application No. EP15196309.7, Response to the Communication Pursuant to Article 15(1) of the Rules of Procedure of the Boards of Appeal mailed on Mar. 16, 2023, 23 pages. [cited by applicant]
European Application No. EP15196309.7, Statement of Grounds of Appeal mailed on Sep. 7, 2021, 44 pages. [cited by applicant]
European Application No. EP15196309.7, Submission Concerning Oral Proceedings on Jul. 18, 2023, mailed on May 17, 2023, 12 pages. [cited by applicant]
European Application No. EP15196309.7, Summons to attend Oral Proceeding mailed on Mar. 6, 2020, 11 pages. [cited by applicant]
European Application No. EP15196309.7, Summons to Attend Oral Proceedings mailed on Sep. 29, 2020, 8 pages. [cited by applicant]
European Application No. EP15196309.7, Summons to Oral Proceedings mailed on Sep. 28, 2022, 3 pages. [cited by applicant]
European Application No. EP15196309.7, Transmittal of Decision/Summons—Opposition mailed on Apr. 28, 2021, 78 pages. [cited by applicant]
European Application No. EP16856410.2, European Search Report mailed on Apr. 25, 2019, 9 pages. [cited by applicant]
European Application No. EP3025719, Notice of Opposition mailed on Jun. 26, 2019, 34 pages. [cited by applicant]
Epstein et al., Morphological and Virological Investigations on Cultured Burkitt Tumor Lymphoblasts (Strain Raji), Journal of the National Cancer Institute, vol. 37, No. 4, Oct. 1966, pp. 547-559. [cited by applicant]
Falkenburg et al., T Cell Therapy in Allogeneic Stem Cell Transplantation, Biology of Blood and Marrow Transplantation, vol. 14, Jan. 2008, 8 pages. [cited by applicant]
Gill et al., Preclinical Targeting of Human Acute Myeloid Leukemia and Myeloablation Using Chimeric Antigen Receptor-Modified T Cells, Blood, vol. 123, No. 15, Apr. 10, 2014, pp. 2343-2354. [cited by applicant]
Gomes-Silva et al., CD7-Edited T Cells Expressing a CD7-Specific CAR for the Therapy of T-cell Malignancies, Blood, vol. 130, No. 3, Jul. 20, 2017, pp. 285-296. [cited by applicant]
Grupp et al., Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia, The New England Journal of Medicine, vol. 368, No. 16, Apr. 18, 2013, pp. 1509-1518. [cited by applicant]
Henig et al., Hematopoietic Stem Cell Transplantation—50 Years of Evolution and Future Perspectives, Rambam Maimonides Medical Journal, vol. 5, No. 4, Oct. 29, 2014, pp. 1-15. [cited by applicant]
Henry et al., Identification of an Alternative CD20 Transcript Variant in B-Cell Malignancies Coding for a Novel Protein Associated to Rituximab Resistance, Blood, vol. 115, No. 12, Mar. 25, 2010, pp. 2420-2429. [cited by applicant]
Hermansen et al., Inconsistent Immunohistochernical Expression Patterns of Four Different CD133 Antibody Clones in Glioblastoma, The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry So… [cited by applicant]
Hinrichs et al., Reassessing Target Antigens for Adoptive T-cell Therapy, Nature Biotechnology, vol. 31, No. 11, Nov. 2013, pp. 999-1008. [cited by applicant]
Holmes, CD45: All is Not Yet Crystal Clear, Immunology, vol. 117, No. 2, Feb. 2006, pp. 145-155. [cited by applicant]
Jaiswal et al., CD47 is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis, Cell, vol. 138, No. 2, Jul. 23, 2009, 24 pages. [cited by applicant]
Janeway et al., The Immune System in Health and Disease, Immunobiology, Jan. 1994, 5 pages. [cited by applicant]
Kebriaei et al., Infusing CD-19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-cell Transplantation for Advanced B-lymphoid Malignancies, Human Gene Therapy, vol. 23, No… [cited by applicant]
Kim et al., Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia, Cell, vol. 173, No. 6, May 31, 2018, 35 pages. [cited by applicant]
Kim et al., Precision Genome Engineering with Programmable DNA-Nicking Enzymes, Genome Research, vol. 22, No. 7, Apr. 2012, pp. 1327-1333. [cited by applicant]
Klein et al., Epitope Interactions of Monoclonal Antibodies Targeting CD20 and Their Relationship to Functional Properties, MAbs, vol. 5, No. 1, Jan.-Feb. 2013, pp. 22-33. [cited by applicant]
Kolb, Graft-Versus-Leukemia Effects of Transplantation and Donor Lymphocytes, Blood, vol. 112, No. 12, Dec. 1, 2008, pp. 4371-4383. [cited by applicant]
Koo et al., Measuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9, Molecules and Cells, vol. 38, No. 6, Jun. 2015, pp. 475-481. [cited by applicant]
Kuijpers et al., CD20 Deficiency in Humans Results in Impaired T Cell-Independent Antibody Responses, Journal of Clinical Investigation, vol. 120, No. 1, Jan. 4, 2010, pp. 214-222. [cited by applicant]
Lamers et al., Treatment of Metastatic Renal Cell Carcinoma with CAIX CAR-Engineered T Cells: Clinical Evaluation and Management of On-Target Toxicity, Molecular Therapy, vol. 21, No. 4, Apr. 2013, pp. 904-912. [cited by applicant]
Laplana et al., Association of BST-2 Gene Variants with HIV Disease Progression Underscores the Role of BST-2 in HIV Type 1 Infection, The Journal of Infectious Diseases, vol. 207, No. 3, Feb. 1, 2013, 33 pages. [cited by applicant]
Lascorz et al., Association Study Identifying Polymorphisms in CD47 and other Extracellular Matrix Pathway Genes as Putative Prognostic Markers for Colorectal Cancer, International Journal of Colorectal Disease, vol. 28… [cited by applicant]
Leisegang et al., MHC-Restricted Fratricide of Human Lymphocytes Expressing Survivin-specific Transgenic T Cell Receptors, Journal of Clinical Investigation, vol. 120, No. 11, Nov. 2010, pp. 3869-3877. [cited by applicant]
Mali et al., RNA-Guided Human Genome Engineering via Cas9, Science, vol. 339, No. 6121, Feb. 15, 2013, pp. 823-826. [cited by applicant]
Manghwar et al., CRISPR/Cas Systems in Genome Editing: Methodologies and Tools for sgRNA Design, Off-Target Evaluation, and Strategies to Mitigate Off-Target Effects, Advanced Science, vol. 7, No. 6, Mar. 2020, pp. 1-16. [cited by applicant]
Marelli-Berg et al., An Immunologist's Guide to CD31 Function in T-cells, Journal of Cell Science, vol. 126, Jun. 1, 2013, pp. 2343-2352. [cited by applicant]
Morgan et al., Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced with a Chimeric Antigen Receptor Recognizing ERBB2, Molecular Therapy, vol. 18, No. 4, Apr. 2010, pp. 843-851. [cited by applicant]
Morgan et al., Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRVIII and Development of Adoptive Cell Therapy for Glioma, Human Gene Therapy, vol. 23, No. 10, Oct. 2012, pp. 1043-1053. [cited by applicant]
Murphy et al., Janeway's Immunobiology, Seventh Edition, Garland Science, 2008, 26 pages. [cited by applicant]
Pohl et al., Pharmacogenetic Profiling of CD133 is Associated with Response Rate (RR) and Progression-free Survival (PFS) in Patients with Metastatic Colorectal Cancer (mCRC), Treated with Bevacizumab-based Chemotherapy… [cited by applicant]
Porter et al., Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia, The New England journal of Medicine, vol. 365, No. 8, Aug. 25, 2011, pp. 725-733. [cited by applicant]
Roberts et al., CD45-Deficient Severe Combined Immunodeficiency Caused by Uniparental Disomy, Proceedings of the National Academy of Sciences USA, vol. 109, No. 26, Jun. 26, 2012, pp. 10456-10461. [cited by applicant]
Schendel et al., Limitations for TCR Gene Therapy by MHC-Restricted Fratricide and TCR-Mediated Hematopoietic Stem Cell Toxicity, Oncoimmunology, vol. 2, No. 1, Jan. 2013, pp. e22410-1-e22410-3. [cited by applicant]
Schnittger et al., D324N Single-nucleotide Polymorphism in the FLT3 Gene is Associated with Higher Risk of Myeloid Leukemias, Genes, Chromosomes & Cancer, vol. 45, No. 4, Apr. 2006, pp. 332-337. [cited by applicant]
Shono et al., Bone Marrow Graft-Versus-Host Disease: Early Destruction of Hematopoietic Niche After MHC-Mismatched Hematopoietic Stem Cell Transplantation, Blood, vol. 115, No. 26, Jul. 1, 2010, pp. 5401-5411. [cited by applicant]
Stanton et al., A High-frequency Polymorphism in Exon 6 of the CD45 Tyrosine Phosphatase Gene (PTPRC) Resulting in Altered Isoform Expression, Proceedings of the National Academy of Sciences of the United States of Amer… [cited by applicant]
Taniguchi et al., 2B4 Inhibits NK-Cell Fratricide, Blood, vol. 110, No. 6, Sep. 15, 2007, pp. 2020-2023. [cited by applicant]
Tebas et al., Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV, The New England Journal of Medicine, vol. 370, No. 10, Mar. 6, 2014, 17 pages. [cited by applicant]
Teeling et al., The Biological Activity of Human CD20 Monoclonal Antibodies is Linked to Unique Epitopes on CD20, The Journal of Immunology, vol. 177, No. 1, Jul. 1, 2006, pp. 362-371. [cited by applicant]
Uchiyama et al., Development of Novel Humanized Anti-CD20 Antibodies Based on Affinity Constant and Epitope, Cancer Science, vol. 101, No. 1, Jan. 1, 2010, pp. 201-209. [cited by applicant]
Ukena et al., Human Regulatory T Cells in Allogeneic Stem Cell Transplantation, Blood, vol. 118, No. 13, Sep. 29, 2011, pp. e82-e92. [cited by applicant]
Urnov et al., Genome Editing with Engineered Zinc Finger Nucleases, Nature Reviews Genetics, Document D44, vol. 11, No. 9, Sep. 2010, pp. 636-646. [cited by applicant]
Vera et al., T Lymphocytes Redirected Against the Kappa Light Chain of Human Immunoglobulin Efficiently Kill Mature B Lymphocyte-Derived Malignant Cells, Blood, vol. 108, No. 12, Dec. 1, 2006, pp. 3890-3897. [cited by applicant]
Wang et al., HM1.24 (CD317) is a Novel Target Against Lung Cancer for Immunotherapy Using Anti-HM1.24 Antibody, Cancer Immunology, Immunotherapy: CII, vol. 58, No. 6, Jun. 2009, pp. 967-976. [cited by applicant]
Wang et al., State-Of-The-Art Human Gene Therapy Part 1 Gene Delivery Technologies, Discovery Medicine, vol. 18, 2014, 67-77 pages. [cited by applicant]
Wang et al., State-Of-The-Art Human Gene Therapy Part 1. Gene Delivery Technologies, Abstract, Discovery Medicine, vol. 18, 2014, 2 pages. [cited by applicant]
Zebedee et al., Comparison of Mouse Ly5 and Ly5b Leucocyte Common Antigen Alleles, Developmental Immunology, vol. 1, No. 4, Feb. 1991, pp. 243-254. [cited by applicant]
Zernich et al., Natural HLA Class I Polymorphism Controls the Pathway of Antigen Presentation and Susceptibility to Viral Evasion, Journal of Experimental Medicine, vol. 200, No. 1, Jul. 5, 2004, pp. 13-24. [cited by applicant]
Zikherman et al., Quantitative Differences in CD45 Expression Unmask Functions for CD45 in B-cell Development, Tolerance, and Survival, Proceedings of the National Academy of Sciences of the United States of America, vo… [cited by applicant]
Holt et al., “Human Hematopoietic Stem/Progenitor Cells Modified by Zinc-Finger Nucleases Targeted to CCR5 Control HIV-1 in Vivo”, Nature Biotechnology, vol. 28, No. 8, Aug. 2010, pp. 839-847. [cited by applicant]
Uchida et al., “Mouse CD20 Expression and Function”, International Immunology, vol. 16, No. 1, Jan. 2004, pp. 119-129. [cited by applicant]
Cited By (1)
US 12,521,434